Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098240 · ClinicalTrials.gov registry record · Phase 2
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 297
- Enrollment target
NCT01098240 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 297 participants.
The verdict
NCT01098240, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 297 participants
- Enrollment target
Study Summary
The primary objectives of this study are to: 1) Evaluate the efficacy of CP 601,927 compared to placebo in the augmentation of antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) using the Montgomery Asberg Depression Rating Scale (MADRS). 2) Evaluate the safety and tolerability of CP 601,927 in patients with MDD on ADT.
Interventions
- OTHER Placebo
- DRUG CP-601,927
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2010-06-14 |
| Est. Completion | 2011-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01098240
The ClinicalTrials.gov registry entry for NCT01098240 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01098240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01098240 about?
NCT01098240 is a clinical study titled "A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression". The primary objectives of this study are to: 1) Evaluate the efficacy of CP 601,927 compared to placebo in the augmentation of antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) using the Montgomery Asberg Depression Rating Scale (MADRS). 2) Evaluate the safety and tolerab...
What is the current status of trial NCT01098240?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 297 participants. The study started on 2010-06-14. Estimated completion is 2011-09-12.
What interventions are being tested in trial NCT01098240?
The interventions under investigation include: Placebo (OTHER), CP-601,927 (DRUG).
Who is sponsoring clinical trial NCT01098240?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.